세계의 치료제 모니터링(TDM) 시장 : 제품별, 기술별, 약물군별, 치료 분야별, 검체별, 최종사용자별 - 예측(-2029년)

Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029

US $ 4,950 ￦ 6,907,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,279,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,372,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,954,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 치료제 모니터링(TDM) 시장 규모는 2024년 23억 달러에서 2029년까지 34억 4,000만 달러에 달할 것으로 예상되며, 연평균 8.4%의 건전한 성장세를 보일 것으로 예상됩니다.

면역분석 기술의 발전은 여전히 이 성장의 주요 촉진제이며, 이 부문의 궤도에 긍정적인 영향을 미치고 있습니다. 이러한 기술은 강화 화학발광, ELISA, 형광증강 등 약물 모니터링의 정확성, 속도 및 특이성을 향상시키는 것을 목표로 합니다. 한편, 의료진은 TDM이 치료 결과를 개선하는 데 있어 TDM의 중요성을 더 잘 인식하고 있으며, 이는 임상 현장에 TDM을 도입하는 데 도움이 되고 있습니다. 교육 및 트레이닝을 통해 임상의들이 TDM의 이점을 더 잘 이해하고 일상 진료에 쉽게 도입할 수 있도록 돕고 있습니다. 이러한 요소들이 총체적으로 역동적으로 성장하는 시장 환경에 영향을 미치고 있습니다.

조사 범위
조사 대상 연도	2022-2029년
기준 연도	2023년
예측 기간	2024-2029년
단위	달러
부문	제품, 기술, 약물군, 치료 영역, 검체, 최종사용자, 지역
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가

"제품별로는 소모품 부문이 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다."

치료제 모니터링(TDM)에서 소모품 부문은 가장 높은 CAGR을 기록할 것으로 예상됩니다. 시약, 어세이 키트, 캘리브레이터와 같은 소모품은 암, 심혈관질환, 신경 질환과 같이 만성적이고 치료가 복잡한 질환의 치료제를 일상적으로 모니터링하는 데 필수적이기 때문에 TDM 시장에서 매우 중요한 역할을 하고 있습니다. 맞춤형 치료에 대한 관심이 높아지고 정확한 약물 수준 평가에 대한 필요성이 증가함에 따라 고품질 소모품에 대한 수요가 증가하고 있습니다. 또한, 연구소와 병원이 첨단 TDM 시스템에 투자하는 자금은 관련 제품에 대한 수요를 증가시켜 시장 확장을 촉진할 수 있습니다.

"표본별로는 혈액 부문이 예측 기간 동안 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다."

혈액은 TDM에 가장 많이 사용되는 시료로, 혈장 및 혈청 내 약물 농도를 정확하고 직접적으로 측정할 수 있다는 점에서 시장을 주도하고 있습니다. 혈액의 채취와 처리에 대한 확립된 프로토콜이 있어 신뢰성과 일관성이 보장됩니다. 또한, 면역분석, LC-MS/MS 등 최첨단 기술과 호환되어 약물을 정확하게 정량할 수 있어 치료 모니터링의 최신 요구사항을 충족시킬 수 있습니다. 또한, 혈액을 이용한 TDM을 지지하는 규제 가이드라인과 임상 관행에 의해 뒷받침되고 있습니다. 용량 최적화를 위한 약동학 모니터링에서 그 이점이 입증되어 치료 결과를 개선하고 있으며, 이 모든 것이 임상 현장에서의 채택에 유리하게 작용하고 있습니다.

"미국이 북미 약물 모니터링 시장에서 가장 높은 CAGR로 성장할 것입니다."

미국에서는 심혈관질환, 당뇨병, 신경 질환, 암과 같은 만성질환의 유병률이 증가하면서 TDM에 대한 수요가 증가하고 있습니다. 이러한 질병 중 일부는 부작용을 줄이기 위한 조치를 취하여 치료 효과를 최적화하기 위해 철저한 모니터링이 필요하기 때문에 TDM 기술 채택 속도가 빨라지고 있습니다. 또한, 중국의 의료 체계가 잘 구축되어 있고, 많은 병원, 연구소, 진단 센터가 존재하기 때문에 선진적인 엔드-투-엔드 통합을 더욱 촉진하고 있습니다. 또한, 수많은 제약 및 생명공학 기업의 존재로 뒷받침되는 TDM 기술의 끊임없는 혁신은 모니터링 도구의 가용성과 진보를 보장합니다. 이러한 모든 요인들이 결합되어 미국 TDM 시장의 급격한 성장에 박차를 가하고 있습니다.

이 보고서는 세계 치료제 모니터링(TDM) 시장을 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 상황, 향후 동향 등의 정보를 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

• 치료제 모니터링(TDM) 시장 개요
• 아시아태평양의 치료제 모니터링(TDM) 시장 점유율 : 약물 종류별, 국가별(2023년)
• 치료제 모니터링(TDM) 시장 : 주요 국가별
• 치료제 모니터링(TDM) 시장 : 지역 구성(2024-2029년)
• 치료제 모니터링(TDM) 시장 : 개발도상 시장 vs. 선진 시장

제5장 시장 개요

• 소개
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 가격 분석
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• 규제 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동
  • 아프리카
• 무역 분석
• 특허 분석
• 주요 회의와 이벤트(2025년·2026년)
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 투자와 자금 조달 시나리오
• 치료제 모니터링(TDM) 시장에 대한 생성형 AI의 영향

제6장 치료제 모니터링(TDM) 시장 : 제품별

• 소개
• 소모품
• 장비
  • 면역분석기
  • 크로마토그래피·MS 검출기
  • 임상화학 분석기

제7장 치료제 모니터링(TDM) 시장 : 기술별

• 소개
• 면역분석
  • ELISA
  • 화학발광면역측정
  • 형광 면역분석
  • 비색 면역분석
  • 기타 면역측정
• 크로마토그래피 - MS
  • 액체 크로마토그래피 - 질량 분석
  • 가스 크로마토그래피 - 질량 분석
• 기타 기술

제8장 치료제 모니터링(TDM) 시장 : 약물 종류별

• 소개
• 항간질제
• 항부정맥제
• 면역억제제
• 항생제
• 기관지확장제
• 향정신제
• 기타 약제

제9장 치료제 모니터링(TDM) 시장 : 치료 분야별

• 소개
• 신경질환
• 심장병
• 감염증
• 종양
• 기타 치료 분야

제10장 치료제 모니터링(TDM) 시장 : 검체별

• 소개
• 혈액
• 타액
• 기타 검체

제11장 치료제 모니터링(TDM) 시장 : 최종사용자별

• 소개
• 병원 검사실
• 상업·민간 검사실
• 기타 최종사용자

제12장 치료제 모니터링(TDM) 시장 : 지역별

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
• 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
• 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 호주
  • 기타 아시아태평양
• 라틴아메리카
• 중동 및 아프리카
• GCC 국가

제13장 경쟁 구도

• 개요
• 강점
• 주요 기업이 채용한 전략
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 스타트업/중소기업
• 기업 평가와 재무 지표
• 제품/브랜드의 비교
• 경쟁 시나리오

제14장 기업 개요

• 주요 기업
  • ABBOTT
  • THERMO FISHER SCIENTIFIC INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • SIEMENS HEALTHINEERS AG
  • DANAHER CORPORATION
  • BIO-RAD LABORATORIES, INC.
  • BIOMERIEUX SA
  • BIOSYNEX SA
  • GRIFOLS, S.A.
  • EXAGEN INC.
  • ARK DIAGNOSTICS, INC.
  • R-BIOPHARM AG
  • RANDOX LABORATORIES LTD.
• 기타 기업
  • APDIA GROUP
  • BBI SOLUTIONS
  • EAGLE BIOSCIENCES, INC.
  • JASEM LABORATORY SYSTEMS AND SOLUTIONS
  • AALTO SCIENTIFIC, LTD.
  • IMMUNDIAGNOSTIK AG
  • UTAK
  • SEKISUI MEDICAL CO., LTD.
  • DIASYSTEM SCANDINAVIA AB
  • CAMBRIDGE LIFE SCIENCES LIMITED
  • CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
  • BUHLMANN LABORATORIES AG
  • SJK GLOBAL, LLC
  • EPITOPE DIAGNOSTICS, INC.
  • QED BIOSCIENCE INC.
  • BODITECH MED INC.
  • IMMUNODIAGNOSTIC SYSTEMS

제15장 부록

ksm

영문 목차

영문목차

It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD)
Segments	By Product, Technology, Drug Class, Therapeutic Area, Specimen, End User, and Region
Regions covered	North America, Europe, APAC, Latin America, Middle East & Africa, and GCC Countries.

"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."

The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation. Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.

"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."

Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose , which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.

"US to grow at the highest CAGR for North America therapeutic drug monitoring market"

The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoringmarketplace.

• By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
• By Designation: C-level Executives - 30%, Directors - 34%, and Others - 36%
• By Region: North America- 40%, Europe - 25%, Asia Pacific- 19%, Latin America- 8%, Middle East & Africa- 6% and GCC Countries- 2%

The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).

Research Coverage

This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders , Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Gountries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Importance of therapeutic drug monitoring in organ transplant procedures, Use of therapeutic drug monitoring across various therapeutic fields, Increasing preferences for precision medicine, Growing focus on R&D related to therapeutic drug monitoring, Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, Increase in prevalence of Epilepsy, Rising prevalence of cancer to drive adoption of Therapeutic Drug Monitoring in Oncology Treatments), restraints (High capital investments, Reluctance of small hospitals to offer therapeutic drug monitoring services), opportunities (Significant opportunities in BRICS countries, Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring, Integration of AI and machine learning), and challenges (Alternatives to conventional therapeutic drug monitoring, Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries, Shortage of skilled professionals) influencing the growth of the therapeutic drug monitoring market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the therapeutic drug monitoring market
• Market Development: Comprehensive information about lucrative markets - the report analyses the therapeutic drug monitoring market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK)) among others in therapeutic drug monitoring market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Lab-based analysis
    • 2.2.1.3 Approach 3: Drug class-based analysis
    • 2.2.1.4 Approach 4: Presentations of companies and primary interviews
    • 2.2.1.5 Growth forecast
    • 2.2.1.6 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 STUDY LIMITATIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
• 4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE, BY DRUG CLASS AND COUNTRY (2023)
• 4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY
• 4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029
• 4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Importance of therapeutic drug monitoring in organ transplant procedures
    • 5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields
    • 5.2.1.3 Increasing preference for precision medicine
    • 5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring
    • 5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    • 5.2.1.6 Increasing prevalence of epilepsy
    • 5.2.1.7 Rising prevalence of cancer
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments
    • 5.2.2.2 Reluctance of small hospitals to offer therapeutic drug monitoring services
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Significant opportunities in BRICS countries
    • 5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
    • 5.2.3.3 Integration of AI and machine learning
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Alternatives to conventional therapeutic drug monitoring
    • 5.2.4.2 Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries
    • 5.2.4.3 Shortage of skilled professionals
• 5.3 PRICING ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 NORTH AMERICA
    • 5.7.1.1 US
    • 5.7.1.2 Canada
  • 5.7.2 EUROPE
  • 5.7.3 ASIA PACIFIC
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
  • 5.7.4 LATIN AMERICA
  • 5.7.5 MIDDLE EAST
  • 5.7.6 AFRICA
• 5.8 TRADE ANALYSIS
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
• 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGY
    • 5.12.1.1 Enzyme-linked immunosorbent assay
  • 5.12.2 COMPLEMENTARY TECHNOLOGY
    • 5.12.2.1 Liquid chromatography-mass spectrometry
  • 5.12.3 ADJACENT TECHNOLOGY
    • 5.12.3.1 Electrophoresis
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 THREAT OF SUBSTITUTES
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
• 6.3 EQUIPMENT
  • 6.3.1 IMMUNOASSAY ANALYZERS
    • 6.3.1.1 High efficiency to drive adoption
  • 6.3.2 CHROMATOGRAPHY & MS DETECTORS
    • 6.3.2.1 Technological advancements to propel growth
  • 6.3.3 CLINICAL CHEMISTRY ANALYZERS
    • 6.3.3.1 Increasing incidence of chronic and complex diseases to drive market

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
    • 7.2.1.1 Accurate measurement of target-specific proteins to drive market
  • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
    • 7.2.2.1 Rapid detection time and good specificity to support growth
  • 7.2.3 FLUORESCENCE IMMUNOASSAYS
    • 7.2.3.1 High operability and better sensitivity of FIAs to drive market
  • 7.2.4 COLORIMETRIC IMMUNOASSAYS
    • 7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
  • 7.2.5 OTHER IMMUNOASSAYS
• 7.3 CHROMATOGRAPHY-MS
  • 7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.1.1 High accuracy to drive demand for LC-MS
  • 7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.2.1 Drawbacks of GC-MS to challenge market growth
• 7.4 OTHER TECHNOLOGIES

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

• 8.1 INTRODUCTION
• 8.2 ANTIEPILEPTIC DRUGS
  • 8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
• 8.3 ANTIARRHYTHMIC DRUGS
  • 8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
• 8.4 IMMUNOSUPPRESSANT DRUGS
  • 8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
• 8.5 ANTIBIOTIC DRUGS
  • 8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
• 8.6 BRONCHODILATOR DRUGS
  • 8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
• 8.7 PSYCHOACTIVE DRUGS
  • 8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
• 8.8 OTHER DRUGS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 NEUROLOGICAL DISORDERS
  • 9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 9.3 CARDIOLOGY
  • 9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
• 9.4 INFECTIOUS DISEASES
  • 9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
• 9.5 ONCOLOGY
  • 9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
• 9.6 OTHER THERAPEUTIC AREAS

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN

• 10.1 INTRODUCTION
• 10.2 BLOOD
  • 10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
• 10.3 SALIVA
  • 10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
• 10.4 OTHER SAMPLES

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITAL LABORATORIES
  • 11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET
• 11.3 COMMERCIAL & PRIVATE LABORATORIES
  • 11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
• 11.4 OTHER END USERS

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.2.2 US
    • 12.2.2.1 Increasing awareness regarding precision medicine to propel market
  • 12.2.3 CANADA
    • 12.2.3.1 Availability of funding for research to offer growth opportunities
• 12.3 EUROPE
• 12.4 EUROPE: MACROECONOMIC OUTLOOK
  • 12.4.1 GERMANY
    • 12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
  • 12.4.2 UK
    • 12.4.2.1 Increasing cases of chronic diseases to drive market
  • 12.4.3 FRANCE
    • 12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
  • 12.4.4 ITALY
    • 12.4.4.1 Rising incidence of cancer to drive demand
  • 12.4.5 SPAIN
    • 12.4.5.1 Adoption of technologically advanced immunoassays to boost market
  • 12.4.6 REST OF EUROPE
• 12.5 ASIA PACIFIC
• 12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.6.1 JAPAN
    • 12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
  • 12.6.2 CHINA
    • 12.6.2.1 Rising number of organ transplants to boost market
  • 12.6.3 INDIA
    • 12.6.3.1 Rising incidence of cancer to propel market
  • 12.6.4 AUSTRALIA
    • 12.6.4.1 High healthcare expenditure and favorable government initiatives to propel market
  • 12.6.5 REST OF ASIA PACIFIC
• 12.7 LATIN AMERICA
  • 12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
  • 12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
• 12.8 MIDDLE EAST & AFRICA
  • 12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
  • 12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
• 12.9 GCC COUNTRIES
  • 12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
  • 12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 RIGHT TO WIN
• 13.3 STRATEGIES ADOPTED BY KEY PLAYERS
• 13.4 REVENUE ANALYSIS
• 13.5 MARKET SHARE ANALYSIS
• 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 13.6.1 STARS
  • 13.6.2 EMERGING LEADERS
  • 13.6.3 PERVASIVE PLAYERS
  • 13.6.4 PARTICIPANTS
  • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.6.5.1 Company footprint
    • 13.6.5.2 Region footprint
    • 13.6.5.3 Product footprint
    • 13.6.5.4 Technology footprint
    • 13.6.5.5 End-user footprint
• 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
  • 13.7.1 PROGRESSIVE COMPANIES
  • 13.7.2 RESPONSIVE COMPANIES
  • 13.7.3 DYNAMIC COMPANIES
  • 13.7.4 STARTING BLOCKS
  • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 13.7.5.1 Detailed list of key startups/SMEs
• 13.8 COMPANY VALUATION & FINANCIAL METRICS
  • 13.8.1 FINANCIAL METRICS
  • 13.8.2 COMPANY VALUATION
• 13.9 PRODUCT/BRAND COMPARISON
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ABBOTT
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 MnM view
      • 14.1.1.3.1 Key strengths
      • 14.1.1.3.2 Strategic choices
      • 14.1.1.3.3 Weaknesses and competitive threats
  • 14.1.2 THERMO FISHER SCIENTIFIC INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 SIEMENS HEALTHINEERS AG
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 DANAHER CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 BIO-RAD LABORATORIES, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
      • 14.1.6.3.2 Deals
  • 14.1.7 BIOMERIEUX SA
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 BIOSYNEX SA
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
  • 14.1.9 GRIFOLS, S.A.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 EXAGEN INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Deals
  • 14.1.11 ARK DIAGNOSTICS, INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 R-BIOPHARM AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
  • 14.1.13 RANDOX LABORATORIES LTD.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 APDIA GROUP
  • 14.2.2 BBI SOLUTIONS
  • 14.2.3 EAGLE BIOSCIENCES, INC.
  • 14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
  • 14.2.5 AALTO SCIENTIFIC, LTD.
  • 14.2.6 IMMUNDIAGNOSTIK AG
  • 14.2.7 UTAK
  • 14.2.8 SEKISUI MEDICAL CO., LTD.
  • 14.2.9 DIASYSTEM SCANDINAVIA AB
  • 14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
  • 14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
  • 14.2.12 BUHLMANN LABORATORIES AG
  • 14.2.13 SJK GLOBAL, LLC
  • 14.2.14 EPITOPE DIAGNOSTICS, INC.
  • 14.2.15 QED BIOSCIENCE INC.
  • 14.2.16 BODITECH MED INC.
  • 14.2.17 IMMUNODIAGNOSTIC SYSTEMS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

관련자료